Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features

Touria Derkaoui1*, Joaira Bakkach1, Mohamed Mansouri1,2, Ali Loudiyi2, Mohamed Fihri3, Fatima Zahra Alaoui1, Amina Barakat1, Bouchra El Yemlahi1, Hassan Bihri1, Naima Ghailani Nourouti1 and Mohcine Bennani Mechita1

Abstract

Background: Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population originated or resident in the North of Morocco.

Methods: We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010 and January 2015. Clinicopathologic and prognostic features have been analyzed. Disease-Free Survival (DFS) and Overall Survival (OS) have been estimated.

Results: Of all cases, forty-nine (17.6%) were identified as having triple negative breast cancer with a median age of 46 years. The average tumor size was 3.6 cm. The majority of patients had invasive ductal carcinoma (91.8%) and 40.4 % of them were grade III SBR. Nodal metastasis was detected in 38.9 % of the patients and vascular invasion was found in 36.6 % of them. About half of the patients had an early disease (53.1 %) and 46.9 % were diagnosed at an advanced stage. Patients with operable tumors (61.2 %) underwent primary surgery and adjuvant chemotherapy. Patients with no operable tumors (26.5 %) received neoadjuvant chemotherapy followed by surgery, and patients with metastatic disease (12.2 %) were treated by palliative chemotherapy. DFS and OS at 5 years were respectively 83.7 and 71.4 %. Among 49, twelve had recurrences, found either when diagnosing them or after a follow-up. Local relapse was 6.1 %. Lung and liver metastases accounted consecutively for 8.2 and 10.2 %. Bone metastases were found in 4.1 % and brain metastases in 2.1 % of the cases.

Conclusion: Our results are in accordance with literature data, particularly what concerning young age and poor prognosis among TNBC phenotype. Therefore, the identification of BRCA mutations in our population seems to be essential in order to better adapt management options for this aggressive form of breast cancer.

Keywords: Triple negative breast cancer, BRCA1, BRCA2, Prognostic, Clinicopathologic, Survival analysis

Background

Breast cancer is a heterogeneous disease encompassing various clinical, morphological and molecular distinct subtypes. In the early 2000s, through RNA expression profile analysis of breast cancer, Perou and Sorlie have identified five main molecular subtypes: Luminal A, Luminal B, ERBB2, Basal-Like (BL) and Normal-Like (NL), bringing out a new classification of this disease and identifying groups with distinct biology and prognosis [1].

In clinical practice, BL tumors are often treated as triple negative breast cancers (TNBCs), tumors which are defined using immunohistochemical methods. TNBCs are characterized by lack of expression of hormone receptors (HR, Estrogen ER and Progesterone PR) and human epidermal growth factor receptor 2 (HER2). This breast cancer...
cancer phenotype accounts for approximately 17 % in most published series (10 ~ 20 %) [2–4].

TNBC is over-represented among non-menopausal African descent women and is characterized by a high BRCA mutation rate [2, 5–8]. Patients with TNBC are more likely to experience relapse within the first 3 years and are at high risk of death in the first 5 years following diagnosis. Furthermore, TNBC exhibits a high frequency of metastasis compared to other breast cancer phenotypes with distinct metastatic patterns, particularly in visceral and cerebral sites [3, 9–12].

We present here the first study aiming to analyze clinico-pathologic and prognostic features of triple negative breast cancer in a Mediterranean population originated or resident in the North of Morocco.

Methods
Patients
We describe a retrospective study of breast cancer in a Mediterranean population originated or resident in the North of Morocco. This population represent 10.5 % of the total Moroccan population. After reviewing data of the Oncology Clinic Al Amal of Tangier, a total of 279 breast cancer cases were registered between January 2010 and January 2015. In this work only patients diagnosed with TNBC were recruited.

Methods
Estrogen and progesterone receptors were evaluated on fixed and paraffin-embedded tissue using immunohistochemical methods. The threshold set out for HR negativity was a lack (< 1 % positivity) of any ER and PR immunoreactivity. HER2 was considered negative if immunohistochemical stains were reported 0, 1+ or if HER2 FISH showed no gene amplification.

All tumors were classified following histological classification (WHO 2003). Histological grading was performed using Scarff-Bloom-Richardson classification (SBR) as modified by Elston-Ellis (mSBR). Tumors were classified according to the TNM system 2010 and regrouped into American Joint Committee on Cancer stages (AJCC 2010).

Disease-Free Survival (DFS) and Overall Survival (OS) were assessed using Kaplan-Meier analysis [13]. DFS was determined from the time of diagnosis to the date of tumor relapse or last follow-up. OS was defined as the time between date of diagnosis and death or last follow-up. Survival according to AJCC stages was also estimated, early (I, II) and advanced (III, IV) stages. The Log-Rank test was used to examine the statistical significance of the differences observed between the two groups early and advanced. This test was performed at a 5 % level.

Participants provide written informed consent. Ethic approval for the study was obtained through the Ethics Committee for Biomedical Research in the Faculty of Medicine and Pharmacy of Rabat (CERB).

Results
Among 279 patients diagnosed with breast cancer, forty-nine (17.6 %) were identified as triple negative. The median age at diagnosis was 46 and was ranging from 28 to 90 years. Approximately two thirds of patients (63.6 %) were non-menopausal and 24.4 % had a family history of breast cancer. The main ethnic groups of our population are Arabs (69.4 %) and Amazigh (26.6 %). Europeans and sub-Saharan represent only 2 % each.

The average tumor size was 3.6 cm. The overwhelming majority of patients (91.8 %) had an infiltrating ductal carcinoma, and 8.2 % of cases had infiltrating lobular carcinoma. High-grade tumors represented 40.4 % of cases, the intermediate 55.3 % and low-grade was only 4.3 %. Regarding lymph node involvement, 38.9 % of patients had positive lymph nodes at initial diagnosis and a lympho-vascular invasion was found in 36.6 % of cases. Patients with stage I accounted for 12.2 %, stage II (40.8 %), stage III (34.7 %) and 12.2 % had metastatic disease (stage IV)(Table 1).

Patients with operable tumors (T1–T2–T3, N0–N1) which represent 61.2 % in our series, underwent primary surgery and adjuvant chemotherapy. Patients with no operable tumors (T4, N2–N3) (26.5 %) received neoadjuvant chemotherapy followed by surgery. Metastatic cancers (12.2 %) received palliative chemotherapy. Breast-conserving surgery was performed in 31.6 % of cases, either immediately or after neoadjuvant chemotherapy (Table 2).

The majority of patients received radiotherapy (70.7 %). Patients who underwent breast-conserving surgery, breast irradiation was systematically performed in negative lymph nodes cases (77.8 %). For patients with lymph nodes metastasis, nodal irradiation was constantly indicated (22.2 %). About patients who underwent radical surgery, chest wall irradiation was applied in the absence of lymph node invasion, at 64.7 % considering the TN status as a poor prognostic factor indicating radiotherapy. Chest wall and nodal complete irradiation was performed for patients who have positive lymph nodes (35.3 %).

Five years disease-free survival for patients with localized disease was 83.7 %. The overall 5 years survival for all patients was 71.4 % (Table 3, Figs. 1 and 2). Patients diagnosed in an advanced stage had shorter survival rate than those diagnosed at early stage (47.8 % versus 92.3 % consecutively, with pvalue = 0.002 < 0.05 (Table 3, Fig. 3).

Among 49 patients, 12 had recurrence either at diagnosis or after follow-up. In this group, local recurrence was 6.1 %. The distribution of metastatic sites was as
Table 1  Clinicopathologic characteristics of the population study

| Variable                          | Frequency |
|----------------------------------|-----------|
| TNBC                             | 17.6 %    |
| Median age at diagnosis          | 46 ans    |
| Ethnicity                        |           |
| Arab                             | 69.4 %    |
| Amazigh                          | 26.6 %    |
| Sub-Saharan                      | 2 %       |
| European                         | 2 %       |
| Menopause                        |           |
| Yes                              | 36.4 %    |
| No                               | 63.6 %    |
| Breast cancer family history     |           |
| Present                          | 24.4 %    |
| Absent                           | 75.6 %    |
| Tumor size                       |           |
| T1                               | 10.2 %    |
| T2                               | 73.5 %    |
| T3                               | 12.2 %    |
| T4                               | 4.1 %     |
| Histological type                |           |
| Invasive ductal carcinoma        | 91.8 %    |
| Invasive lobular carcinoma       | 8.2 %     |
| SBR grading                      |           |
| I                                | 4.3 %     |
| II                               | 55.3 %    |
| III                              | 40.4 %    |
| Lymphovascular invasion          |           |
| Present                          | 36.6 %    |
| Absent                           | 63.4 %    |
| Lymph node status                |           |
| N0                               | 61.1 %    |
| N1                               | 25 %      |
| N2                               | 5.6 %     |
| N3                               | 8.3 %     |
| Metastasis at initial diagnosis  |           |
| M0                               | 87.8 %    |
| M1                               | 12.2 %    |
| TNM stage                        |           |
| I                                | 12.2 %    |
| II                               | 40.8 %    |
| III                              | 34.7 %    |
| IV                               | 12.2 %    |
| Distant metastasis               |           |
| MO                               | 86 %      |
| M1                               | 14 %      |
| Recurrence sites                 |           |
| Local                            | 6.1 %     |
| Bone                             | 4.1 %     |
| Liver                            | 10.2 %    |
| Lung                             | 8.2 %     |
| Brain                            | 2.1 %     |

Table 2  Treatment modalities for all patients

| Procedure                          | Frequency |
|------------------------------------|-----------|
| Surgery                            |           |
| Radical surgery                    | 68.4 %    |
| Conservative surgery               | 31.6 %    |
| Chemotherapy                       |           |
| Adjuvant                           | 61 %      |
| Neoadjuvant                        | 26.8 %    |
| Palliative                         | 12.2 %    |
| Radiotherapy                       |           |
| Yes                                | 70.7 %    |
| No                                 | 29.3 %    |

following: lung (8.2 %), liver (10.2 %), bone (4.1 %) and brain (2.1 %)(Table 1).

Discussion

Triple negative breast cancer frequency reported in the present work (17.6 %) is consistent with national [14, 15] and international data [2–4]. This frequency varies according to race/ethnicity and positivity threshold set out for HR and HER2 expression [2, 16, 17]. Morocco is a country of northwestern Africa whose population is characterized by ethnic diversity. Arab and Amazigh present the majority of this population that contain also other groups as Jewish, European and sub-Saharan. Ethnic composition of our series bears a great resemblance to that of the whole country. Arab and Amazigh are predominant (96 %). As our case-series is limited, we cannot give any conclusion about TNBC distribution. Furthermore, to the best of our knowledge, there is no data about TNBC frequency among these ethnic groups.

TNBC occurs more frequently at a younger age, often before menopause compared with other breast cancer subtypes [3]. In the current study, the median age was 46 years and the majority of our patients were non-menopausal (63.6 %). Early age of onset for breast cancer can reflect a genetic predisposition in particular mutations of BRCA1 and BRCA2 genes. A strong correlation has been described between the BRCA pathway and triple negative breast cancers. The prevalence of germline mutations in BRCA genes among triple negative patients varies between 9 and 20 % [18–21].

Table 3  Outcome of the triple negative group

| Kaplan-Meier survival result          | 83.7 % |
|--------------------------------------|--------|
| Disease free survival                | 83.7 % |
| Overall survival at 5 years          | 71.4 % |
| Early                               | 92.3 % |
| Advanced                             | 47.8 % |
Although somatic mutations in BRCA1 gene represent about 40%, there is a highly dysfunction in BRCA1 within tumor cells by other mechanisms, notably epigenetic modifications like gene methylation [20, 22–24].

Inactivation of BRCA1 gene, which is commonly described between BRCA1 mutations carriers and TNBC, is responsible for a dysfunction of DNA repair. Hence, this pathway could be exploited therapeutically by poly (ADP-ribose) polymerase inhibitors (PARP), repair enzymes for single strand breaks in DNA, which is the only repair pathway available currently [25–27]. Besides, this similarity has nowadays important implications in clinical management by genetic testing for germline BRCA1 mutations, notably in young premenopausal woman, even without a family history. In the present study, 24.4% of patients had a familial history of breast cancer. According to the Guidelines of National Comprehensive Cancer Network, TNBC has become a supplementary individual criterion for genetic testing. A genetic study of BRCA genes involving all patients included in this work is ongoing.

Clinically, TN tumors are often large [3]. In this study, the mean diameter was 3.6 cm. This could be related to rapid growth of this subtype of tumors and to its relatively high incidence in young patients who present difficulties in mammography detection.

The great majority of TN tumors are invasive ductal carcinomas (Invasive Breast Carcinomas of No Special Type (NST), WHO classification 2012) with high histologic grade. Interestingly, some TNBCs comprise special histological subtypes with a favorable prognosis, such as adenoid cystic carcinoma (called cylindrome) and Juvenile secretory carcinoma [28, 29]. None of these histological subtypes was reported in the present study.

Traditionally, as tumor size increases, the rate of lymph node involvement increases. This correlation was not observed in our group study. The majority of tumors (85.7%) had a diameter superior than 2 cm, paradoxically, 61.1% of patients were negative for nodal involvement. These results are consistent with those found in literature data [3, 30].

Triple negative breast tumors have demonstrated high chemosensitivity. Such tumors responded in the neoadjuvant setting and have showed complete pathologic response (pCR) generally higher than non-TNBCs. This is the “paradox of TNBC” [31–34].

For patients with inoperable disease (large size, inflammatory tumor, etc.), neoadjuvant chemotherapy provides a means to improve further surgery. Moreover, it gives the opportunity to propose later, depending on the quality and the terms of response, a breast-conserving surgery improving thus the cosmetic and preserving more women’s body image.
Regarding patients with operable disease, neoadjuvant chemotherapy allows in one hand to test in vivo the treatment effectiveness and to predict pCR rate, which is a good prognostic factor. On the other hand, it provides necessary time to genetic testing for BRCA mutations especially among women aged under 50. This allows guiding management process for mutation carriers. Radical surgery would be recommended. Preventive measures, such as prophylactic surgery could be also discussed. In the present study, the rates of advanced and metastatic cancers are higher (46.9 and 12.2 % respectively). This is due mainly to lack of early detection in our population. Therefore, implementation of a national organized screening program for breast cancer is essential.

The correlation between TN status and increased risk of local recurrence remains controversial. Some studies did not show an increased risk. Solin et al. [35] revealed that local recurrence rate at 8 years was 8% compared to 4% in non-TNBC. Freedman et al. [36] have reported, by analyzing three groups HR+, HER2 and TN, that the local recurrence rates at 5 years were similar in the three groups (2.3, 4.6 and 3.2 % respectively). However in Nguyen et al. [37] study, the rate of local recurrence at 5 years was significantly higher in the TN group compared with Luminal A and B cancers (7.1 % versus 0.8 % and 1.5 %). In the present study, the local recurrence rate was 6.1 %.

The TN group presents a significant risk of recurrence within the first 3 years and death during the 5 years following initial diagnosis [3, 9], the risk of relapse declines rapidly thereafter. After 8 years of follow up, recurrence is exceptional [3].

Metastatic progression is characterized by predominance of visceral sites (notably liver and brain) and lower incidence of bone metastases [9–12]. In the current study, we showed a high rate of visceral metastases including liver (10.2 %) and lungs (8.2 %), but a lower rate of brain metastases (2.1 %). Bone metastases were found in 4.1 % of cases.

Prognosis for TN cancers remains pejorative compared to other subtypes, whether in terms of disease-free survival or overall survival [2, 3, 38, 39]. DFS and OS at 5 years were respectively 83.7 and 71.4 %. Most recurrences were recorded in the first 2 to 3 years following diagnosis. These results are in accordance with literature data [3, 9].

The TNBCs diagnosed at an early stage presented a five-year survival rate which is strikingly higher (92.3 %) than advanced TNBCs (47.8 %). Early detection is therefore one of the most powerful strategies in reducing cancer mortality and improving chances of recovery.

**Conclusion**

The characteristics of TNBC among our population study are consistent with international literature data, especially concerning young age at diagnosis, poor prognosis and pejorative survival. Further research studies for determining BRCA abnormalities will lead to a better understanding the genetic profile of our population.

The identification of germline BRCA mutations in triple negative breast tumors seems essential to adapt the therapeutic strategy and to ensure adequate clinical management for mutation carriers and their relatives.

At the somatic level, characterization of molecular defects in triple negative tumors mainly BRCA and p53, are promising for new targeted therapeutic approaches. This is the case of PARP inhibitors that target the inactivation of the enzyme poly (ADP-ribose) polymerase, the only pathway so far available for DNA breaks repair.

**Abbreviations**

DFS: Disease-free survival; ER: Estrogen receptor; FISH: Fluorescence in situ hybridization; HER2: Human epidermal growth factor receptor 2; HR: Hormone receptors; NST: No special type; OS: Overall survival; PARP: Poly (ADP-ribose) polymerase; pCR: Complete pathologic response; PR: Progesterone receptor; SBR: Scarff-Bloom-Richardson; TNBC: Triple negative breast cancer; WHO: World Health Organization

**Acknowledgments**

We wish to thank the team of Human Genomic Research Laboratory at the Faculty of Sciences and Techniques of Tangier and the team of Oncology Clinic Al Amal of Tangier for their help and support. We would particularly like to thank Mr Iraki Ali for his proof reading.

**Funding**

The authors have no support or funding to report.

**Availability of data and materials**

The datasets analyzed during the current study will be available from the corresponding author on reasonable request.

**Authors' contributions**

DT contributed for the study conception, design, writing of the manuscript, acquisition of data and analysis. BJ and MM participated in the design of the study, drafting the manuscript, and helped with data and analysis. BM helped in the statistical analysis. LA, AFZ, BA, EB, BH and GNN contributed to the revision of the manuscript. BMM approved the analyzed literature data and have given approval of the final manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable for this study.

**Ethics approval and consent to participate**

The study was approved by the Ethics Committee for Biomedical Research of the Faculty of Medicine and Pharmacy of Rabat (CERB) registered under number IORG0006594. All participants gave a written informed consent to participate in the study.

**Author details**

1 Human Genomic Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, Tangier, Morocco. 2 Oncology Clinic Al Amal of Tangier, Tangier, Morocco. 3 Mathematics and Applications Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, Tangier, Morocco.

**Received:** 18 May 2016  **Accepted:** 11 October 2016  **Published online:** 22 October 2016
References

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the california breast cancer study. Jama. 2006;295(21):2492–502.

3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–44.

4. Foulikes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.

5. Foulikes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, et al. Estrogen receptor status in brca1 and brca2-related breast cancer the influence of age, grade, and histological type. Clin Cancer Res. 2004;10(6):2029–34.

6. Greenup R, Buchanan A, Lorizio W, Marcom PK, et al. Prevalence of brca mutations among women with triple-negative breast cancer (tnbc) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254–58.

7. Young S, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, King RM, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King JA, et al. Breast cancer risk in women with hereditary breast cancer and a negative family history. Breast Cancer Res Treat. 2009;115(2):423–8.

8. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–77.

9. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.

10. Carev LA, Dyer G, Vanderpool IA, Smear J, Forceville K, Brouwers B, Neven P, Janssens H, Deraedt K, Moerman P, Van Calster B, et al. Triple-negative breast cancer: clinical characteristics in the different histological subtypes. Breast. 2013;22(5):761–6.

11. Foulikes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, et al. Disruption of the olaparib in brca1-deficient advanced breast cancer. In: ASCO Annual Meeting Proceedings. 2009. p. 501.

12. Yerushalmi R, Hayes M, Gelmon K. Breast carcinoma–rare types: review associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373–8.

13. Topal AE, Brown ML, Mehta S, Li J, Voduc D, Gelmon K. Breast carcinoma–rare types: review of the literature. Ann Oncol. 2009;245.

14. van der Valk P, van de Velde CJH, Nielsen TO, van den Belt-Dusemple P, et al. Meta-analysis results from the collaborative trials on neoadjuvant breast cancer (ctneobc). Cancer Res. 2012;72(24 Suppl):1–11.

15. Beca F, Santos R, Vieira D, Zefirolo L, Dufloth R, Schmitt F. Primary breast cancer in African Americans and Caucasians: an epidemiological and molecular factors between African american and caucasian women with triple-negative breast cancer. Breast Cancer. 2014;14(1):1.

16. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, et al. Incidence and outcome of brca mutations in unselected patients with triple-receptor-negative breast cancer. Clin Cancer Res. 2011;17(S):1082–9.

17. Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, Rudnicka H, Lubinski J, Scott RJ. Prevalence of brca1 and brca2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80.

18. Severson TM, Peeters M, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeyer T, et al. Brca1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol Oncol. 2015;9(8):1528–38.

19. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miorn P, Olson JE, Goddwin AK, Parkvist KS, Olsowd C, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–11.

20. Vincent-Salomon A, Macrogrogan G, Charafie-Jauffret E, Jacquerie J, Arnaud L. Identification of basal-like carcinomas in clinical practice: triple zero/brc1-like carcinomas. Bull Cancer. 2010;97(3):357–63.

21. Yamashita N, Tokunaga E, Kita T, Hitchens M, Inoue Y, Tanaka K, Yasuda M, Taketani T, Aokiishi S, Okada S, et al. Epigenetic inactivation of brca1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer. Clin Breast Cancer. 2015;15(6):498–504.

22. Kawachi A, Otsuki-Takada E, Shimoi T, Shimomura A, Kodama M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Ushijima T, et al. 98bpbrca1 methylation in triple-negative breast cancer. Ann Oncol. 2015;26(suppl 9):98–9.

23. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Robertson TB, Santarosa M, Dillon KN, Hickson I, Knights C, et al. Targeting the dna repair defect in breast mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

24. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mercuri-Roelvink M, Mortimer P, Swisland H, Lau A, O’Connor MJ, et al. Inhibition of poly (adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med. 2006;354(12):123–34.

25. Tutt A, Robison M, Garber J, Domshek S, Audeh M, Weitzel J, Friedlander M, Carmichael J. Phase ii trial of the oral parp inhibitor olaparib in brca-deficient advanced breast cancer. In: ASCO Annual Meeting Proceedings. 2009. p. 501.

26. Dreyer G, Vandorpe T, Smeets A, Forceville K, Brouwers B, Neven P, Janssens H, Deraedt K, Moerman P, Van Calster B, et al. Triple-negative breast cancer: clinical characteristics in the different histological subtypes. Breast. 2013;22(5):761–6.
38. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–74.

39. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Supplement 1):1–11.